NO20045023L - Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer - Google Patents

Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Info

Publication number
NO20045023L
NO20045023L NO20045023A NO20045023A NO20045023L NO 20045023 L NO20045023 L NO 20045023L NO 20045023 A NO20045023 A NO 20045023A NO 20045023 A NO20045023 A NO 20045023A NO 20045023 L NO20045023 L NO 20045023L
Authority
NO
Norway
Prior art keywords
crystals
steroids
pharmaceutical formulations
preparation
particle size
Prior art date
Application number
NO20045023A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Mueller
Annette Eichardt
Hagen Gerecke
Sabine Gliesing
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045023L publication Critical patent/NO20045023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet en fremgangsmåte for fremstilling av krystaller av steroider hvis gjennomsnittlige partikkelstørrelse Ugger i et på forhånd gitt orm-åde og hvis maksimale partikkelstørrelse ikke overskrider en på forhånd gitt verdi, hvorved en overmettet oppløsning av steroidene under krystalhsasjonen underkastes en våtmaling ved hjelp av en irmretning for våtmaling, hvorved en primærkomsuspensjon oppnås. Det er videre beskrevet ved derme fremgangsmåten oppnåelige krystaller samt farmasøytiske formuleringer irmeholdende disse.
NO20045023A 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer NO20045023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
NO20045023L true NO20045023L (no) 2004-11-18

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045023A NO20045023L (no) 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Country Status (20)

Country Link
US (1) US7148212B2 (no)
EP (1) EP1497308B1 (no)
JP (1) JP4490116B2 (no)
KR (1) KR20040106380A (no)
CN (1) CN1646555A (no)
AT (1) ATE340186T1 (no)
AU (1) AU2003232491A1 (no)
BR (1) BR0309357A (no)
CA (1) CA2480004C (no)
DE (2) DE10218107A1 (no)
DK (1) DK1497308T3 (no)
ES (1) ES2274258T3 (no)
IL (1) IL163986A0 (no)
MX (1) MXPA04010467A (no)
NO (1) NO20045023L (no)
PL (1) PL371340A1 (no)
PT (1) PT1497308E (no)
RU (1) RU2315056C2 (no)
WO (1) WO2003091272A1 (no)
ZA (1) ZA200409401B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
PL1886694T3 (pl) * 2006-08-10 2009-11-30 Jenapharm Gmbh Doustna postać leku do antykoncepcji
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
CN106458851B (zh) 2014-05-13 2019-01-11 阿克苏诺贝尔化学品国际有限公司 将螯合剂结晶的方法
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
EP4151219A4 (en) 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
AU624421B2 (en) 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
ES2126976T3 (es) 1991-07-10 1999-04-01 Chiyoda Chem Eng Construct Co Procedimento para la produccion de aducto cristalino de bisfenol a y fenol y aparato para este.
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995018018A1 (en) * 1993-12-27 1995-07-06 Nippon Soda Co. Ltd. 4-hydroxy-4'-isopropoxydiphenyl sulfone developer composition, wet pulverizing method, and dispersion
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
AU1798300A (en) * 1998-12-25 2000-07-31 Fuji Chemical Industries, Ltd. Method for producing calcium pantothenate
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
IL163986A0 (en) 2005-12-18
CN1646555A (zh) 2005-07-27
ATE340186T1 (de) 2006-10-15
ZA200409401B (en) 2006-02-22
BR0309357A (pt) 2005-02-22
JP2005524698A (ja) 2005-08-18
EP1497308A1 (de) 2005-01-19
DK1497308T3 (da) 2007-01-29
PT1497308E (pt) 2007-01-31
CA2480004A1 (en) 2003-11-06
EP1497308B1 (de) 2006-09-20
PL371340A1 (en) 2005-06-13
RU2004134324A (ru) 2006-02-10
DE10218107A1 (de) 2003-11-20
AU2003232491A1 (en) 2003-11-10
ES2274258T3 (es) 2007-05-16
MXPA04010467A (es) 2004-12-13
CA2480004C (en) 2007-11-13
WO2003091272A1 (de) 2003-11-06
RU2315056C2 (ru) 2008-01-20
JP4490116B2 (ja) 2010-06-23
US7148212B2 (en) 2006-12-12
DE50305122D1 (de) 2006-11-02
KR20040106380A (ko) 2004-12-17
US20030216360A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
NO20045023L (no) Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
WO2003002196A3 (en) Multi-site ventricular pacing system measuring qrs duration
WO2001023390A3 (de) Azepinoindol-derivate, deren herstellung und anwendung
CA2369070A1 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
NZ579082A (en) Stable suspensions of micronised particles of a solid organic compound which is free of surfactants, thickeners, poly-electrolytes or block copolymers
CA2192731A1 (en) Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof
AU4025689A (en) Method of using plant nucleoside derivatives for treatment of viral infections
NO995431L (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
BG103959A (en) Carbocyclic nucleoside hemisulphate and its application in the treatment of viral infections
HRP20020167B1 (en) Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms
DE60335910D1 (de) Verfahren zur herstellung von siliciumdioxid aus olivin
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
AU6431398A (en) Stimulation, culture and preservation of pancreatic and other cells
CA2316739A1 (en) Preparation of cells for production of biologicals
US5968249A (en) Process for preparing silica pigment
CN103755758A (zh) 一种制霉菌素的制备方法
ATE178051T1 (de) Verfahren zur herstellung einer physikalisch stabilen, kristallinen gamma-modifikation von para-aminobenzolsulfonamid
DuCHESNE Hybridization in the Methyl Radical of CH3X Molecules
IE791438L (en) Oxadiazolotriazines
JPS51113882A (en) Method for preparing 1-(alpha -alkoxyalkyl)-uracil derivatives
JPS537519A (en) Concentrating method for titanium component
JPH0347071A (ja) カンゾン根茎細胞のグリチルリチン高生産株取得方法
JPS56137895A (en) Direct saccharification of milo
Devyatkina et al. Use of Organic Complexformers During the Etching of Titanium

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application